BIO-key Faces Going Concern Warning, Nasdaq Delisting, and Significant Impairment Amidst Mounting Losses
BKYI sits 27% above its 52-week low of $3.1 on light trading volume (0.1× avg).
Summary
BIO-key International's annual report highlights a going concern warning, Nasdaq delisting, a $2.5 million investment impairment, and increased net losses, despite raising capital through dilutive financing.
Key Events · Corporate Governance and Compliance · BKYI
-
Going Concern Warning Issued
The independent auditor included an explanatory paragraph in their opinion, citing substantial doubt about the company's ability to continue as a going concern due to a history of losses, negative operating cash flow, and dependence on external financing.
-
Nasdaq Delisting and OTC Transition
The company's common stock was suspended from Nasdaq on May 13, 2026, and moved to OTC Markets due to non-compliance with minimum bid price and late periodic filings. An appeal hearing is scheduled for June 16, 2026.
-
Significant Investment Impairment
BIO-key recorded a $2.5 million (50%) impairment charge on its investment in Boumarang, Inc. for the year ended December 31, 2025, due to unachieved anticipated revenues. This represents 58% of the company's current market capitalization.
-
Increased Net Loss and Cash Burn
The company reported a net loss of $7.16 million in 2025, up from $4.30 million in 2024. Net cash used in operating activities increased to $4.67 million in 2025 from $2.91 million in 2024.
Analysis · BKYI · Technology
This annual report reveals critical financial distress and compliance issues for BIO-key. The auditor's 'going concern' warning, coupled with the Nasdaq delisting and a substantial investment impairment, indicates severe operational and financial challenges. While the company raised significant capital through warrant exercises and secured notes, this was necessary to offset increasing losses and cash burn, and it came with considerable dilution. The future of the company's listing and its ability to achieve profitability remain highly uncertain.
At the time of this filing, BKYI was trading at $3.95 on OTC in the Technology sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $3.10 to $19.70. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.